Michael Thomas Henderson's Net Worth

$82.4 Million

Estimate Recalculated Jun 30, 2025 09:50PM EST

Who is Michael Thomas Henderson

Michael Thomas Henderson has an estimated net worth of $82.4 Million. This is based on reported shares across multiple companies, which include BridgeBio Pharma, Inc., ARYA Sciences Acquisition Corp IV, Spyre Therapeutics, Inc., and Apogee Therapeutics, Inc..

SEC CIK

Michael Thomas Henderson's CIK is 0001779990

Past Insider Trading and Trends

2020 was Michael Thomas Henderson's most active year for acquiring shares with 27 total transactions. Michael Thomas Henderson's most active month to acquire stocks was the month of April. 2020 was Michael Thomas Henderson's most active year for disposing of shares, totalling 51 transactions. Michael Thomas Henderson's most active month to dispose stocks was the month of June. 2019 saw Michael Thomas Henderson paying a total of $119,000.00 for 180,767 shares, this is the most they've acquired in one year. In 2024 Michael Thomas Henderson cashed out on 125,000 shares for a total of $4,088,505.09, their largest year based on trade value.

Loading...

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

BridgeBio Pharma, Inc.

Chief Business Officer
Updated Dec 17, 2020
Form 4
9.79K
Dec 17, 2020
9.79K
Grant
Dec 15
Form 4
-3.42%
-10.00K
$26.29
-$504.70K
Dec 02, 2020
282.49K
Sale
ScheduledDec 01
Form 4
-0.30%
-784.00
$30.04
-$23.55K
Dec 02, 2020
261.40K
Sale
ScheduledJun 03
Form 4
-3.35%
-16.35K
$22.90
-$731.63K
Nov 18, 2020
471.87K
Sale
ScheduledNov 16
Form 4
-3.27%
-10.00K
$19.70
-$373.06K
Nov 03, 2020
296.03K
Sale
ScheduledNov 02
Form 4
-3.16%
-10.00K
$19.81
-$380.35K
Oct 05, 2020
306.03K
Sale
ScheduledOct 01
Form 4
-3.51%
-10.00K
$20.11
-$397.79K
Sep 22, 2020
274.57K
Sale
ScheduledSep 18
Form 4
-3.48%
-10.00K
$14.45
-$285.73K
Sep 03, 2020
277.24K
Sale
ScheduledSep 01
Form 4
-1.17%
-5.46K
$28.53
-$155.77K
Aug 18, 2020
459.94K
Options
Aug 16
Form 4
-3.45%
-10.00K
$13.77
-$272.14K
Aug 05, 2020
279.78K
Sale
ScheduledAug 03
Form 4
-3.34%
-10.00K
$15.57
-$308.10K
Jul 06, 2020
289.78K
Sale
ScheduledJul 01
Form 4
-0.23%
-606.00
$30.01
-$18.19K
Jun 10, 2020
260.29K
Sale
ScheduledJun 08
Form 4
-0.98%
-2.58K
$29.37
-$75.91K
Jun 03, 2020
261.68K
Sale
ScheduledJun 01
Form 4
$1.05
$19.28K
May 27, 2020
264.27K
Options
May 26
Form 4
273.53%
444.11K
May 21, 2020
606.47K
Grant
May 19
Form 4
-0.89%
-1.46K
$30.47
-$44.49K
May 06, 2020
162.36K
Sale
ScheduledMay 05
Form 4
-2.33%
-3.90K
$29.52
-$115.27K
May 05, 2020
163.82K
Sale
ScheduledMay 01 - May 04
Form 4
-1.52%
-2.58K
$26.94
-$69.63K
Apr 03, 2020
167.73K
Sale
ScheduledApr 01
Form 4
-2.28%
-3.98K
$32.44
-$128.97K
Mar 04, 2020
170.31K
Sale
ScheduledMar 02
Form 4
-2.23%
-3.98K
$34.90
-$138.73K
Feb 05, 2020
174.29K
Sale
ScheduledFeb 03
Form 4
-2.18%
-3.98K
$33.17
-$131.86K
Jan 06, 2020
178.26K
Sale
ScheduledJan 02 - Jan 03
Form 4
4.03%
7.00K
$17.00
Jul 03, 2019
180.77K
Purchase
Jul 01
Form 3
Jun 27, 2019
Showing 23 results

ARYA Sciences Acquisition Corp IV

Investor
Updated Jul 31, 2024
Form 4
-100.00%
-30.00K
Jul 31, 2024
Disposition
Jul 31
Form 3
Feb 25, 2021
Showing 2 results

Spyre Therapeutics, Inc.

Investor
Updated May 16, 2024
Form 4
11.32K
May 16, 2024
11.32K
Grant
May 14
Form 3
Jun 30, 2023
Showing 2 results

Apogee Therapeutics, Inc.

Chief Executive Officer
Updated Nov 08, 2024
Form 4
-1.11%
-15.00K
$59.22
-$888.32K
Nov 08, 2024
1.34M
Sale
ScheduledNov 06
Form 4
-2.79%
-40.00K
$47.62
-$1.90M
Sep 06, 2024
1.39M
Sale
ScheduledSep 04
Form 4
-2.71%
-40.00K
$40.62
-$1.62M
Aug 09, 2024
1.43M
Sale
ScheduledAug 07
Form 4
-1.01%
-15.00K
$37.26
-$558.90K
Jul 05, 2024
1.47M
Sale
ScheduledJul 05
Form 4
398.51K
Dec 20, 2023
398.51K
Grant
Dec 18
Form 3/A
Jul 17, 2023
1.49M
Form 3
Jul 13, 2023
1.40M
Showing 7 results